Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.

Felix Chun; Georg C Hutterer; Paul Perrotte; Andrea Gallina; Luc Valiquette; Francois Benard; Michael McCormack; Alberto Briganti; Constantin Ionescu; Claudio Jeldres; Jean-Pierre Guay; Fred Saad; Pierre I Karakiewicz

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.

Standard

Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. / Chun, Felix; Hutterer, Georg C; Perrotte, Paul; Gallina, Andrea; Valiquette, Luc; Benard, Francois; McCormack, Michael; Briganti, Alberto; Ionescu, Constantin; Jeldres, Claudio; Guay, Jean-Pierre; Saad, Fred; Karakiewicz, Pierre I.

In: BJU INT, Vol. 100, No. 1, 1, 2007, p. 37-41.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Chun, F, Hutterer, GC, Perrotte, P, Gallina, A, Valiquette, L, Benard, F, McCormack, M, Briganti, A, Ionescu, C, Jeldres, C, Guay, J-P, Saad, F & Karakiewicz, PI 2007, 'Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.', BJU INT, vol. 100, no. 1, 1, pp. 37-41. <http://www.ncbi.nlm.nih.gov/pubmed/17488305?dopt=Citation>

APA

Chun, F., Hutterer, G. C., Perrotte, P., Gallina, A., Valiquette, L., Benard, F., McCormack, M., Briganti, A., Ionescu, C., Jeldres, C., Guay, J-P., Saad, F., & Karakiewicz, P. I. (2007). Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU INT, 100(1), 37-41. [1]. http://www.ncbi.nlm.nih.gov/pubmed/17488305?dopt=Citation

Vancouver

Chun F, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU INT. 2007;100(1):37-41. 1.

Bibtex

@article{f00c33061ffc4c73ab536fce2214759e,

title = "Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.",

abstract = "OBJECTIVE: To explore the distribution of total prostate specific antigen (PSA) and percentage free/total PSA (%f/tPSA) in healthy volunteers with no clinical evidence of prostate cancer, who participated in prostate cancer screening. SUBJECTS AND METHODS: PSA and %f/tPSA values from 2323 men, who participated in one of three annual prostate cancer screening events between 2004 and 2006, were tabulated according to age strata of 40-49, 50-59, 60-69 and 70-79 years. Local regression smoothing plots provided a graphical display of the relation between age and PSA or %f/tPSA, respectively. All PSA and %f/tPSA analyses were repeated for each age category after excluding, respectively, the top and the bottom 10% of PSA and %f/tPSA values. RESULTS: Within the entire cohort, the median PSA level was 1.0 ng/mL and the median %f/tPSA was 25%. According to the age categories the PSA level and %f/tPSA medians within the entire cohort were, respectively, 0.7, 0.9, 1.3, 1.8 ng/mL and 28.0, 26.0, 24.0 and 25.0%. Of the 2323 men, 438 (18.9%) had a PSA level of >2.5 ng/mL and 1172 (50.5%) had a %f/tPSA of 2.5 ng/mL or a %f/tPSA of 2.5 ng/mL or %f/tPSA of <or = 15% was used, 617 (26.6%) were considered abnormal. CONCLUSION: Half of men with no clinical evidence of prostate cancer should have PSA levels of 25%. A PSA level threshold of 2.5 ng/mL would require a biopsy in 20% of men and a %f/tPSA threshold of <or = 25% in half of the men. Alternatively, a %f/tPSA threshold of <or = 15% would decrease the probability to 15%.",

author = "Felix Chun and Hutterer, {Georg C} and Paul Perrotte and Andrea Gallina and Luc Valiquette and Francois Benard and Michael McCormack and Alberto Briganti and Constantin Ionescu and Claudio Jeldres and Jean-Pierre Guay and Fred Saad and Karakiewicz, {Pierre I}",

year = "2007",

language = "Deutsch",

volume = "100",

pages = "37--41",

journal = "BJU INT",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "1",

}

RIS

TY - JOUR

T1 - Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.

AU - Chun, Felix

AU - Hutterer, Georg C

AU - Perrotte, Paul

AU - Gallina, Andrea

AU - Valiquette, Luc

AU - Benard, Francois

AU - McCormack, Michael

AU - Briganti, Alberto

AU - Ionescu, Constantin

AU - Jeldres, Claudio

AU - Guay, Jean-Pierre

AU - Saad, Fred

AU - Karakiewicz, Pierre I

PY - 2007

Y1 - 2007

N2 - OBJECTIVE: To explore the distribution of total prostate specific antigen (PSA) and percentage free/total PSA (%f/tPSA) in healthy volunteers with no clinical evidence of prostate cancer, who participated in prostate cancer screening. SUBJECTS AND METHODS: PSA and %f/tPSA values from 2323 men, who participated in one of three annual prostate cancer screening events between 2004 and 2006, were tabulated according to age strata of 40-49, 50-59, 60-69 and 70-79 years. Local regression smoothing plots provided a graphical display of the relation between age and PSA or %f/tPSA, respectively. All PSA and %f/tPSA analyses were repeated for each age category after excluding, respectively, the top and the bottom 10% of PSA and %f/tPSA values. RESULTS: Within the entire cohort, the median PSA level was 1.0 ng/mL and the median %f/tPSA was 25%. According to the age categories the PSA level and %f/tPSA medians within the entire cohort were, respectively, 0.7, 0.9, 1.3, 1.8 ng/mL and 28.0, 26.0, 24.0 and 25.0%. Of the 2323 men, 438 (18.9%) had a PSA level of >2.5 ng/mL and 1172 (50.5%) had a %f/tPSA of 2.5 ng/mL or a %f/tPSA of 2.5 ng/mL or %f/tPSA of <or = 15% was used, 617 (26.6%) were considered abnormal. CONCLUSION: Half of men with no clinical evidence of prostate cancer should have PSA levels of 25%. A PSA level threshold of 2.5 ng/mL would require a biopsy in 20% of men and a %f/tPSA threshold of <or = 25% in half of the men. Alternatively, a %f/tPSA threshold of <or = 15% would decrease the probability to 15%.

AB - OBJECTIVE: To explore the distribution of total prostate specific antigen (PSA) and percentage free/total PSA (%f/tPSA) in healthy volunteers with no clinical evidence of prostate cancer, who participated in prostate cancer screening. SUBJECTS AND METHODS: PSA and %f/tPSA values from 2323 men, who participated in one of three annual prostate cancer screening events between 2004 and 2006, were tabulated according to age strata of 40-49, 50-59, 60-69 and 70-79 years. Local regression smoothing plots provided a graphical display of the relation between age and PSA or %f/tPSA, respectively. All PSA and %f/tPSA analyses were repeated for each age category after excluding, respectively, the top and the bottom 10% of PSA and %f/tPSA values. RESULTS: Within the entire cohort, the median PSA level was 1.0 ng/mL and the median %f/tPSA was 25%. According to the age categories the PSA level and %f/tPSA medians within the entire cohort were, respectively, 0.7, 0.9, 1.3, 1.8 ng/mL and 28.0, 26.0, 24.0 and 25.0%. Of the 2323 men, 438 (18.9%) had a PSA level of >2.5 ng/mL and 1172 (50.5%) had a %f/tPSA of 2.5 ng/mL or a %f/tPSA of 2.5 ng/mL or %f/tPSA of <or = 15% was used, 617 (26.6%) were considered abnormal. CONCLUSION: Half of men with no clinical evidence of prostate cancer should have PSA levels of 25%. A PSA level threshold of 2.5 ng/mL would require a biopsy in 20% of men and a %f/tPSA threshold of <or = 25% in half of the men. Alternatively, a %f/tPSA threshold of <or = 15% would decrease the probability to 15%.

M3 - SCORING: Zeitschriftenaufsatz

VL - 100

SP - 37

EP - 41

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 1

M1 - 1

ER -